STAT3 and inflammatory bowel disease: Considering the persistent need for novel treatments for IBD, due to the limitations in efficacy, safety, and patient response rates of current agents such as corticosteroids, immunomodulators, and biologics [16,17], targeting the STAT3 pathway with high specificity and potency offers a compelling therapeutic strategy [18].